In the news: William Carson
Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced the appointment of William Carson as chairman of the board of directors.
Carson, a board-certified psychiatrist, brings over 20 years of experience in the biopharmaceutical industry. He was most recently the president and CEO of Otsuka Pharmaceutical Development & Commercialization, Inc., leading the development and regulatory approvals of Otsuka’s global compounds.
Carson currently serves as chairman of the board of directors of OPDC and is also the chairman of the board of the Sozosei Foundation, a newly established Otsuka charitable organization focused on decriminalization of mental illness. He serves on the boards of Excision BioTherapeutics, Saama and Annexon Biosciences and is trustee of the non-profit Internet2. He is board chair emeritus of the Sphinx Organization, which advocates for parity and inclusion in the arts.
Carson holds an A.B. degree from Harvard College and earned his medical degree from Case Western Reserve University School of Medicine. He completed his residency training in psychiatry at Tufts University School of Medicine. He is a distinguished fellow of the American Psychiatric Association, the National Medical Association and the Executive Leadership Council. Carson was named to Savoy magazine’s 2018 list of the Top 100 Most Influential Blacks in Corporate America. Prior to joining the biopharmaceutical industry, Carson was an associate professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine.